Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 17/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 17/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 17/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29671131 | 0.95 | ITGB1 (0.47) | ITGB1ITGA4ITGB7CNR2 | |
| SCHEMBL22035500 | 0.95 | ITGB1 (0.47) | ITGB1ITGA4ITGB7CNR2 | |
| SCHEMBL22035519 | 0.93 | ITGB1 (0.44) | ITGB1ITGA4ITGB7CNR2KDM4E | |
| SCHEMBL21979211 | 0.89 | ITGA4 (0.54) | ITGB1ITGA4ITGB7 | |
| SCHEMBL21979210 | 0.89 | ITGA4 (0.54) | ITGB1ITGA4ITGB7 | |
| SCHEMBL29671132 | 0.89 | ITGB1 (0.41) | ITGB1ITGA4ITGB7CNR2KDM4E | |
| SCHEMBL22031429 | 0.89 | ITGB1 (0.41) | ITGB1ITGA4ITGB7CNR2KDM4E | |
| SCHEMBL22035516 | 0.88 | ITGB1 (0.46) | ITGB1ITGA4ITGB7CNR2KDM4E | |
| SCHEMBL22035501 | 0.88 | ITGB1 (0.43) | ITGB1ITGA4ITGB7 | |
| SCHEMBL22031422 | 0.88 | ITGB1 (0.39) | ITGB1ITGA4ITGB7CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.